Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies

References

• Stupp R, Mason WP, van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Kang MK, Kang SK. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev. 16(5), 837–847 (2007).
   PubMed Web of Science ®Google Scholar
• Liu G, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5, 67 (2006).
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120), 756–760 (2006).
   PubMed Web of Science ®Google Scholar
• Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat. Med. 12(3), 296–300 (2006).
   PubMed Web of Science ®Google Scholar
• Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64(19), 7011–7021 (2004).
   PubMed Web of Science ®Google Scholar
• Dirks PB. Brain tumor stem cells: bringing order to the chaos of brain cancer. J. Clin. Oncol. 26(17), 2916–2924 (2008).
   PubMed Web of Science ®Google Scholar
• Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat. Rev. Cancer 6(6), 425–436 (2006).
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8(10), 755–768 (2008).
   PubMed Web of Science ®Google Scholar
• Fuchs E, Segre JA. Stem cells: a new lease on life. Cell 100(1), 143–155 (2000).
   PubMed Web of Science ®Google Scholar
• Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11(1), 69–82 (2007).
   PubMed Web of Science ®Google Scholar
• Visvader JE. Cells of origin in cancer. Nature 469(7330), 314–322 (2011).
   PubMed Web of Science ®Google Scholar
• Alcantara Llaguno S, Chen J, Kwon CH et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15(1), 45–56 (2009).
   PubMed Web of Science ®Google Scholar
• Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25(1), 55–57 (2000).
   PubMed Web of Science ®Google Scholar
• Jacques TS, Swales A, Brzozowski MJ et al. Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. EMBO J. 29(1), 222–235 (2010).
   PubMedGoogle Scholar
• Marumoto T, Tashiro A, Friedmann-Morvinski D et al. Development of a novel mouse glioma model using lentiviral vectors. Nat. Med. 15(1), 110–116 (2009).
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang J, Zheng H et al. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell 15(6), 514–526 (2009).
   PubMedGoogle Scholar
• Mani SA, Guo W, Liao MJ et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 133(4), 704–715 (2008).
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Brueckmann I, Scheel C et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108(19), 7950–7955 (2011).
   PubMed Web of Science ®Google Scholar
• Friedmann-Morvinski D, Bushong EA, Ke E et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338(6110), 1080–1084 (2012).
   PubMed Web of Science ®Google Scholar
• Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat. Med. 15(9), 1010–1012 (2009).
   PubMed Web of Science ®Google Scholar
• Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 317(5836), 337 (2007).
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3(7), 730–737 (1997).
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464), 645–648 (1994).
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983–3988 (2003).
   PubMed Web of Science ®Google Scholar
• Hemmati HD, Nakano I, Lazareff JA et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl Acad. Sci. USA 100(25), 15178–15183 (2003).
   PubMed Web of Science ®Google Scholar
• Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63(18), 5821–5828 (2003).
   PubMed Web of Science ®Google Scholar
• O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123), 106–110 (2007).
   PubMed Web of Science ®Google Scholar
• Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65(20), 9328–9337 (2005).
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3), 313–323 (2007).
   PubMed Web of Science ®Google Scholar
• Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65(23), 10946–10951 (2005).
   PubMed Web of Science ®Google Scholar
• Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65(8), 3025–3029 (2005).
   PubMed Web of Science ®Google Scholar
• Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15(3), 504–514 (2008).
   PubMed Web of Science ®Google Scholar
• Fukuda K, Saikawa Y, Ohashi M et al. Tumor initiating potential of side population cells in human gastric cancer. Int. J. Oncol. 34(5), 1201–1207 (2009).
   PubMed Web of Science ®Google Scholar
• Beier D, Hau P, Proescholdt M et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67(9), 4010–4015 (2007).
   PubMed Web of Science ®Google Scholar
• Ogden AT, Waziri AE, Lochhead RA et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 62(2), 505–514; discussion 514 (2008).
   PubMed Web of Science ®Google Scholar
• Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4(5), 440–452 (2009).
   PubMed Web of Science ®Google Scholar
• Sun Y, Liou B, Quinn B, Ran H, Xu YH, Grabowski GA. In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models. PLoS ONE 4(10), e7320 (2009).
   PubMed Web of Science ®Google Scholar
• Read TA, Fogarty MP, Markant SL et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 15(2), 135–147 (2009).
   PubMed Web of Science ®Google Scholar
• Lathia JD, Gallagher J, Heddleston JM et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6(5), 421–432 (2010).
   PubMed Web of Science ®Google Scholar
• Shin HY, Hong YH, Jang SS et al. A role of canonical transient receptor potential 5 channel in neuronal differentiation from A2B5 neural progenitor cells. PLoS ONE 5(5), e10359 (2010).
   Google Scholar
• Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 18(8), 1127–1134 (2009).
   PubMed Web of Science ®Google Scholar
• Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J. Pathol. 223(2), 147–161 (2011).
   PubMed Web of Science ®Google Scholar
• Pece S, Tosoni D, Confalonieri S et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140(1), 62–73 (2010).
   PubMed Web of Science ®Google Scholar
• Laks DR, Masterman-Smith M, Visnyei K et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 27(4), 980–987 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang M, Song T, Yang L et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J. Exp. Clin. Cancer Res. 27, 85 (2008).
   PubMed Web of Science ®Google Scholar
• Zeppernick F, Ahmadi R, Campos B et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14(1), 123–129 (2008).
   PubMed Web of Science ®Google Scholar
• Sato A, Sakurada K, Kumabe T et al.; Tohoku Brain Tumor Study Group. Association of stem cell marker CD133 expression with dissemination of glioblastomas. Neurosurg. Rev. 33(2), 175–183; discussion 183 (2010).
   PubMed Web of Science ®Google Scholar
• Kim KJ, Lee KH, Kim HS et al. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology 31(5), 494–502 (2011).
   PubMed Web of Science ®Google Scholar
• Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 27(8), 844–850 (2009).
   PubMed Web of Science ®Google Scholar
• Cheung AM, Wan TS, Leung JC et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 21(7), 1423–1430 (2007).
   PubMed Web of Science ®Google Scholar
• Morimoto K, Kim SJ, Tanei T et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 100(6), 1062–1068 (2009).
   PubMed Web of Science ®Google Scholar
• Rasheed ZA, Yang J, Wang Q et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl Cancer Inst. 102(5), 340–351 (2010).
   PubMed Web of Science ®Google Scholar
• Chen YC, Chen YW, Hsu HS et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem. Biophys. Res. Commun. 385(3), 307–313 (2009).
   PubMed Web of Science ®Google Scholar
• Rich JN, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell 1(4), 353–355 (2007).
   PubMed Web of Science ®Google Scholar
• Maynard S, Swistowska AM, Lee JW et al. Human embryonic stem cells have enhanced repair of multiple forms of DNA damage. Stem Cells 26(9), 2266–2274 (2008).
   PubMed Web of Science ®Google Scholar
• Smith J, Ladi E, Mayer-Proschel M, Noble M. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc. Natl Acad. Sci. USA 97(18), 10032–10037 (2000).
   PubMed Web of Science ®Google Scholar
• Ito K, Hirao A, Arai F et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431(7011), 997–1002 (2004).
   PubMed Web of Science ®Google Scholar
• Kitange GJ, Carlson BL, Schroeder MA et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-oncology 11(3), 281–291 (2009).
   PubMed Web of Science ®Google Scholar
• Blough MD, Westgate MR, Beauchamp D et al. Sensitivity to temozolomide in brain tumor initiating cells. Neuro-oncology 12(7), 756–760 (2010).
   PubMedGoogle Scholar
• Hermisson M, Klumpp A, Wick W et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J. Neurochem. 96(3), 766–776 (2006).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Sato A, Sunayama J, Matsuda K et al. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells 29(12), 1942–1951 (2011).
   PubMedGoogle Scholar
• Zhou S, Schuetz JD, Bunting KD et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7(9), 1028–1034 (2001).
   PubMed Web of Science ®Google Scholar
• Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5), 555–567 (2007).
   PubMed Web of Science ®Google Scholar
• Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct ‘side population’ of cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA 101(39), 14228–14233 (2004).
   PubMed Web of Science ®Google Scholar
• Bleau AM, Hambardzumyan D, Ozawa T et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4(3), 226–235 (2009).
   PubMed Web of Science ®Google Scholar
• Schaich M, Kestel L, Pfirrmann M et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann. Oncol. 20(1), 175–181 (2009).
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 8(7), 545–554 (2008).
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ, Rich JN. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 7(10), 733–736 (2007).
   PubMed Web of Science ®Google Scholar
• Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol. Med. 17(1–2), 103–112 (2011).
   PubMed Web of Science ®Google Scholar
• Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4), 645–659 (2009).
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66(16), 7843–7848 (2006).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67(8), 3560–3564 (2007).
   PubMed Web of Science ®Google Scholar
• Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120(3), 694–705 (2010).
   PubMed Web of Science ®Google Scholar
• Folkins C, Shaked Y, Man S et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res. 69(18), 7243–7251 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 76(1), 87–93 (2011).
   PubMed Web of Science ®Google Scholar
• Verhoeff JJ, van Tellingen O, Claes A et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9, 444 (2009).
   PubMed Web of Science ®Google Scholar
• Piccirillo SG, Reynolds BA, Zanetti N et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444(7120), 761–765 (2006).
   PubMed Web of Science ®Google Scholar
• Sato A, Sunayama J, Okada M et al. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl. Med. 1(11), 811–824 (2012).
   PubMed Web of Science ®Google Scholar
• Matsuda K, Sato A, Okada M et al. Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. Sci. Rep. 2, 516 (2012).
   PubMedGoogle Scholar
• Di Tomaso T, Mazzoleni S, Wang E et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 16(3), 800–813 (2010).
   PubMed Web of Science ®Google Scholar
• Weng D, Song B, Durfee J et al. Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int. J. Cancer 129(8), 1990–2001 (2010).
   Web of Science ®Google Scholar
• Wang H, Lathia JD, Wu Q et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27(10), 2393–2404 (2009).
   PubMed Web of Science ®Google Scholar
• Brown CE, Starr R, Martinez C et al. Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res. 69(23), 8886–8893 (2009).
   PubMed Web of Science ®Google Scholar
• Ahmed N, Salsman VS, Kew Y et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16(2), 474–485 (2010).
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281–297 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Dutta A, Abounader R. The role of microRNAs in glioma initiation and progression. Front. Biosci. 17, 700–712 (2012).
   Web of Science ®Google Scholar
• Gal H, Pandi G, Kanner AA et al. MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem. Biophys. Res. Commun. 376(1), 86–90 (2008).
   PubMed Web of Science ®Google Scholar
• Godlewski J, Nowicki MO, Bronisz A et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 68(22), 9125–9130 (2008).
   PubMed Web of Science ®Google Scholar
• Li Y, Guessous F, Zhang Y et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 69(19), 7569–7576 (2009).
   PubMed Web of Science ®Google Scholar
• Yu F, Yao H, Zhu P et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 131(6), 1109–1123 (2007).
   PubMed Web of Science ®Google Scholar
• Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 65(7), 2832–2839 (2005).
   PubMed Web of Science ®Google Scholar
• Kurozumi K, Hardcastle J, Thakur R et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol. Ther. 16(8), 1382–1391 (2008).
   PubMed Web of Science ®Google Scholar
• Ulasov IV, Zhu ZB, Tyler MA et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum. Gene Ther. 18(7), 589–602 (2007).
   PubMed Web of Science ®Google Scholar
• Nandi S, Ulasov IV, Rolle CE, Han Y, Lesniak MS. A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy. J. Gene Med. 11(11), 1005–1011 (2009).
   PubMedGoogle Scholar
• Bauerschmitz GJ, Ranki T, Kangasniemi L et al. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res. 68(14), 5533–5539 (2008).
   PubMed Web of Science ®Google Scholar